CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 101 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01417455
NCT01417455N/ACompleted

Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing Spondylitis

Instituto de Medicina Molecular João Lobo Antunes·observational·Posted Aug 16, 2011·Updated Mar 21, 2016

In Brief

An observational study for Rheumatoid Arthritis and 2 related conditions. Completed, enrolled 101 participants across 1 site.

Detailed Summary

Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are characterized by chronic systemic inflammation and share common pathogenic pathways. In both diseases, cytokines like TNF (tumor necrosis factor) and interleukin (IL)-17, known for their pro-inflammatory and osteoclastogenic effects, are relevant players, however, while RA is characterized by bone erosions, AS favors bone overgrowth. Understanding this paradox may hold the key for a better management of both diseases. Our hypothesis is that there are differences in the cellular environment and intracellular signaling between AS and RA. To test this hypothesis we will evaluate the cytokine milieu, the kinetics of bone cells differentiation and their activity in untreated and immunosuppressed RA and AS patients. We will also perform the same observations in patients exposed to targeted treatments.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesPortugal

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 16, 2011
Enrollment StartJan 1, 2012
Primary CompletionJan 1, 2015
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 14.9 years ago